Insider Buying: AEON Biopharma (NASDAQ:AEON) Major Shareholder Purchases $241,500.00 in Stock

AEON Biopharma, Inc. (NASDAQ:AEON) major shareholder Timothy Lynch acquired 1,150,000 shares of the stock in a transaction on Wednesday, August 19th. The stock was bought at an average price of $0.21 per share, with a total value of $241,500.00. Following the completion of the acquisition, the insider directly owned 6,500,000 shares of the company’s stock, valued at $1,365,000. This trade represents a 21.50% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

AEON Biopharma Stock Performance

AEON Biopharma stock opened at $0.19 on Monday. AEON Biopharma, Inc. has a fifty-two week low of $0.18 and a fifty-two week high of $1.45. The stock’s 50 day simple moving average is $0.44 and its two-hundred day simple moving average is $0.78. The stock has a market cap of $4.86 million, a price-to-earnings ratio of 1.07 and a beta of 0.65.

Institutional Trading of AEON Biopharma

An institutional investor recently raised its stake in AEON Biopharma stock. XTX Topco Ltd boosted its stake in shares of AEON Biopharma, Inc. (NASDAQ:AEON) by 251.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 56,852 shares of the company’s stock after buying an additional 40,690 shares during the period. XTX Topco Ltd owned approximately 0.48% of AEON Biopharma worth $63,000 at the end of the most recent reporting period. 22.78% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts recently weighed in on AEON shares. Zacks Research upgraded AEON Biopharma to a “hold” rating in a research report on Wednesday, May 27th. HC Wainwright reissued a “buy” rating and set a $1.20 price objective (down from $5.00) on shares of AEON Biopharma in a research report on Friday, August 14th. Finally, Lake Street Capital initiated coverage on AEON Biopharma in a research report on Thursday, July 30th. They set a “buy” rating and a $1.00 price objective for the company. Three research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, AEON Biopharma currently has a consensus rating of “Moderate Buy” and an average target price of $1.10.

About AEON Biopharma

AEON Biopharma, Inc, formerly Allied Energy Corp., is a clinical‐stage biopharmaceutical company focused on developing and commercializing treatments for rare and orphan diseases. The company applies enzyme replacement and gene therapy platforms to address unmet medical needs in central nervous system and metabolic disorders. Its lead program, AES-103, is being developed as an enzyme replacement therapy for Crigler-Najjar syndrome, a hereditary condition characterized by high levels of unconjugated bilirubin.

Beyond AES-103, AEON Biopharma is advancing AES-201 for X-linked adrenoleukodystrophy (X-ALD), a progressive neurological disorder, and AES-104 for post–COVID-19 conditions, commonly referred to as “long COVID.” These programs are in preclinical or early clinical stages, with ongoing efforts to optimize delivery, evaluate safety profiles and establish proof of concept.